Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer (LA-NSCLC) treated with definitive intent.
Authors
Devarati Mitra
Brigham & Women's Hospital/Dana Farber Cancer Institute, Boston, MA
Devarati Mitra, Vishesh Agarwal, Yu-Hui Chen, Elizabeth H. Baldini, David Allen Barbie, Aileen B. Chen, Benjamin Glass, Gretchen Herman, David E. Kozono, Jonathan Daniel Schoenfeld, Raymond H. Mak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 150)
DOI
10.1200/JCO.2018.36.5_suppl.150
Abstract #
150
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
First Author: Mathilde Cancel
First Author: Jeddeo Paul
Poster
2024 ASCO Annual Meeting
Multiplex analysis of the immune environment before and after neoadjuvant durvalumab as a prognostic factor in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
First Author: Diane Damotte
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu